Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

RecruitingOBSERVATIONAL
Enrollment

3,110

Participants

Timeline

Start Date

August 3, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

December 30, 2026

Conditions
Endometrial CancerCervical CancerAtypical Endometrial HyperplasiaCervical DysplasiaAdnexal MassOvarian Cancer
Interventions
DIAGNOSTIC_TEST

Vaginal Fluid Collection

A sample of vaginal fluid will be collected from each participant, prior to any exams or procedures, by a healthcare provider using a small vaginal swab.

DIAGNOSTIC_TEST

Blood Collection

A blood sample will be collected from each participant prior to undergoing any exams or procedures.

Trial Locations (20)

11414

RECRUITING

The Woman's Health Pavilion, Howard Beach

11590

RECRUITING

The Woman's Health Pavilion, Westbury

32224

RECRUITING

Mayo Clinic, Jacksonville

33029

ACTIVE_NOT_RECRUITING

Signature Women's Healthcare, LLC, Pembroke Pines

33156

ACTIVE_NOT_RECRUITING

My GYN Care, Miami

33173

RECRUITING

Genoma Research, Inc., Miami

34239

RECRUITING

Sarasota Memorial Health Care System, Sarasota

39213

NOT_YET_RECRUITING

University of Mississippi Medical Center, Jackson

44195

RECRUITING

Cleveland Clinic, Cleveland

48602

RECRUITING

Valley OB-GYN Clinic, Saginaw

53226

RECRUITING

Medical College of Wisconsin, Milwaukee

54601

RECRUITING

Mayo Clinic Health System - Southwest Wisconsin, La Crosse

54703

RECRUITING

Mayo Clinic Health System - Northwest Wisconsin, Eau Claire

55905

RECRUITING

Mayo Clinic, Rochester

58206

RECRUITING

Altru Health System, Grand Forks

60637

RECRUITING

University of Chicago, Chicago

60805

ACTIVE_NOT_RECRUITING

Providea Health Partners, LLC, Evergreen Park

70121

RECRUITING

Ochsner Clinic Foundation, New Orleans

77450

RECRUITING

Medical Colleagues of Texas, LLP, Katy

85054

RECRUITING

Mayo Clinic, Phoenix

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05051722 - Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | Biotech Hunter | Biotech Hunter